CAS:1110766-97-6Lusutrombopag

Synonyms: S888711

Lusutrombopag is an agonist of bioavailablethrombopoietin (TPO) receptor that is used to treat chronic liver disease.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

技术信息

CAS号

1110766-97-6

储存条件

分子式

C29H32Cl2N2O5S

运输

蓝冰

分子量

591.55

别名

S888711

溶解度

动物实验配方

生物活性

描述Thrombopoietin (TPO) plays an important role in regulating thrombopoiesis and is a proven therapeutic target to stimulate production of platelets. Lusutrombopag, a small-molecule, TPO receptor agonist, was evaluated as a treatment to raise platelet counts (PCs) in patients with thrombocytopenia and CLD (chronic liver disease) undergoing invasive procedures. Adults with CLD and baseline PCs < 50 × 10⁹/L were randomized to receive once‐daily lusutrombopag 3 mg or placebo ≤ 7 days before an invasive procedure scheduled 2‐7 days after the last dose. 64.8% (70/108) of patients in the lusutrombopag group versus 29.0% (31/107) in the placebo group met the primary endpoint (P < 0.0001; difference of proportion 95% confidence interval [CI], 36.7 [24.9, 48.5]). The median duration of PCs ≥ 50 × 10⁹/L was 19.2 days with lusutrombopag (without platelet transfusion) compared with 0.0 in the placebo group (with platelet transfusion) (P = 0.0001). Those date indicated that lusutrombopag was superior to placebo for reducing the need for platelet transfusions and achieved durable PC response in patients with thrombocytopenia and CLD undergoing invasive procedures ^[3].